Linprixel for relapsed or resistant autoimmune hemolytic anemia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a drug called Linprixel for people with autoimmune hemolytic anemia (AIHA) that has come back or hasn't responded to at least two previous treatments. The goal is to see if it can help control the disease with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of autoimmune hemolytic anemia (wAIHA, cAIHA, or Evans syndrome) that is either relapsed (came back) or refractory (didn't improve after at least two treatments).
- Your hemoglobin level must be 100 g/L or lower.
- If you are on steroids, you must be on a low maintenance dose (15 mg/day or less) for at least 2 weeks before starting.
- If you've had a CD20 monoclonal antibody infusion, it must have been at least 3 months ago.
- You cannot have uncontrolled infections, advanced cancer, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called enatumab for people with warm antibody autoimmune hemolytic anemia (wAIHA) that has come back or not improved after at least two prior treatments. The goal is to see if enatumab can help control the disease.
This trial tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved with standard treatments. The goal is to see if this therapy can help control the disease when other options have failed.
This trial tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. It aims to see if the therapy can help control the disease and improve anemia symptoms.
This Phase 2 trial tests whether taking long-term apixaban (a blood thinner) can prevent venous blood clots in people with autoimmune hemolytic anemia (AIHA). It may help reduce the risk of dangerous clotting events if you meet safety and risk criteria.
This trial tests a drug called linperlisib in people with acquired pure red cell aplasia (aPRCA) that has not responded to at least two prior treatments. The goal is to see if linperlisib can help your body make more red blood cells.
This trial tests a new therapy called META 10-19 for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not responded to or has come back after standard treatments. It aims to see if this treatment can help control the disease.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.